Heather Y Lin1, Isabelle Bedrosian2, Gildy V Babiera2,3, Simona F Shaitelman4, Henry M Kuerer2, Wendy A Woodward4, Naoto T Ueno3,5, Yu Shen1. 1. Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas. 2. Department of Breast Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas. 3. Morgan Welch Inflammatory Breast Cancer Research Program and Clinic, The University of Texas MD Anderson Cancer Center, Houston, Texas. 4. Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas. 5. Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Abstract
BACKGROUND: Guidelines for the treatment of nonmetastatic inflammatory breast cancer (IBC) using trimodality therapy (TT) (chemotherapy, surgery, and radiotherapy) have remained largely unchanged since 2000. However, many patients with nonmetastatic IBC do not receive TT. It is unknown how patient-level (PL) and facility-level (FL) factors contribute to TT use. METHODS: Using the National Cancer Data Base, patients with nonmetastatic IBC who underwent locoregional treatment from 2003 through 2011 were identified. The authors correlated PL factors, including demographic and tumor characteristics, with TT use. An observed-to-expected ratio for the number of patients treated with TT was calculated for each hospital by adjusting for significant PL factors. Hierarchical mixed effects models were used to assess the percentage of variation in TT use attributable to PL and FL factors, respectively. RESULTS: Of the 542 hospitals examined, 55 (10.1%) and 24 (4.4%), respectively, were identified as significantly low and high outliers for TT use (P<.05). The percentage of the total variance in the use of TT attributable to the facility (11%) was nearly triple the variance attributable to the measured PL factors (3.4%). The nomogram generated from multivariate logistic regression of PL factors only allows a facility to assess TT use given their PL data. CONCLUSIONS: FL factors rather than PL factors appear to contribute disproportionately to the underuse of TT in patients with nonmetastatic IBC. To improve treatment guideline adherence for patients with nonmetastatic IBC, it is critical to identify the specific FL factors associated with TT underuse. More organized FL intervention is required to train physicians and to build multidisciplinary teams. Cancer 2017;123:2618-25.
BACKGROUND: Guidelines for the treatment of nonmetastatic inflammatory breast cancer (IBC) using trimodality therapy (TT) (chemotherapy, surgery, and radiotherapy) have remained largely unchanged since 2000. However, many patients with nonmetastatic IBC do not receive TT. It is unknown how patient-level (PL) and facility-level (FL) factors contribute to TT use. METHODS: Using the National Cancer Data Base, patients with nonmetastatic IBC who underwent locoregional treatment from 2003 through 2011 were identified. The authors correlated PL factors, including demographic and tumor characteristics, with TT use. An observed-to-expected ratio for the number of patients treated with TT was calculated for each hospital by adjusting for significant PL factors. Hierarchical mixed effects models were used to assess the percentage of variation in TT use attributable to PL and FL factors, respectively. RESULTS: Of the 542 hospitals examined, 55 (10.1%) and 24 (4.4%), respectively, were identified as significantly low and high outliers for TT use (P<.05). The percentage of the total variance in the use of TT attributable to the facility (11%) was nearly triple the variance attributable to the measured PL factors (3.4%). The nomogram generated from multivariate logistic regression of PL factors only allows a facility to assess TT use given their PL data. CONCLUSIONS: FL factors rather than PL factors appear to contribute disproportionately to the underuse of TT in patients with nonmetastatic IBC. To improve treatment guideline adherence for patients with nonmetastatic IBC, it is critical to identify the specific FL factors associated with TT underuse. More organized FL intervention is required to train physicians and to build multidisciplinary teams. Cancer 2017;123:2618-25.
Keywords:
adherence to treatment guidelines; facility-level factors; nonmetastatic inflammatory breast cancer (IBC); patient- and facility-level factors; trimodality treatment
Authors: Maria C Russell; Y Nancy You; Chung-Yuan Hu; Janice N Cormier; Barry W Feig; John M Skibber; Miguel A Rodriguez-Bigas; Heidi Nelson; George J Chang Journal: JAMA Surg Date: 2013-08 Impact factor: 14.766
Authors: Kenneth W Hance; William F Anderson; Susan S Devesa; Heather A Young; Paul H Levine Journal: J Natl Cancer Inst Date: 2005-07-06 Impact factor: 13.506
Authors: S Dawood; S D Merajver; P Viens; P B Vermeulen; S M Swain; T A Buchholz; L Y Dirix; P H Levine; A Lucci; S Krishnamurthy; F M Robertson; W A Woodward; W T Yang; N T Ueno; M Cristofanilli Journal: Ann Oncol Date: 2010-07-05 Impact factor: 32.976
Authors: Ryaz Chagpar; Yan Xing; Yi-Ju Chiang; Barry W Feig; George J Chang; Y Nancy You; Janice N Cormier Journal: J Clin Oncol Date: 2012-02-21 Impact factor: 44.544
Authors: Mitchel D Armstrong; Alberto V Carli; Hesham Abdelbary; Stephane Poitras; Peter Lapner; Paule E Beaulé Journal: Can J Surg Date: 2018-02 Impact factor: 2.089
Authors: Lauren M Drapalik; Jonathan J Hue; Ashley Simpson; Mary Freyvogel; Lisa Rock; Robert R Shenk; Amanda L Amin; Megan E Miller Journal: Ann Surg Oncol Date: 2022-08-08 Impact factor: 4.339
Authors: Thomas M Schwedhelm; Judy R Rees; Tracy Onega; Ronnie J Zipkin; Andrew Schaefer; Maria O Celaya; Erika L Moen Journal: BMC Cancer Date: 2020-09-03 Impact factor: 4.430